Armata reports Q3 2026 results; net income driven by convertible loan fair value gain
Armata Pharmaceuticals reported grant and award revenue of $3.171 million for the three months ended September 30, 2026 versus $1.159 million in the comparable 2025 period, and a loss from operations of $7.383 million compared with a $7.776 million loss a year earlier. Net income was $54.857 million ($1.15 basic; $(0.24) diluted), primarily driven by a $69.595 million non-cash gain from the change in fair value of the convertible loan, versus a $26.675 million net loss in the comparable 2025 period. Nine-month r...
Read source-backed brief